Abstract: A mechanism for varying the stroke length of an internal combustion engine during each cycle of operation includes a gear set with a first gear non-rotatably mounted to the engine block and a second gear having teeth formed on an inner surface thereof meshing with the first gear to achieve a uniform mechanical crank arm and a variable cam arm for producing a varying length of piston reciprocation throughout the overall stroke cycle of the engine. The orientation of the crank arm and the cam arm relative to the axis of piston reciprocation is selected for causing the crank arm and the cam arm to cooperatively produce a positive torque on the crankshaft at the top dead center position of the piston. The gear set is also selectively configured and dimensioned to achieve a predetermined ratio of the length of the cam arm to the length of the crank arm.

Abstract: A system and a method are disclosed for collecting and tracking ideas. A description of an idea is received by an innovation system from an idea owner. The innovation system sends the description of the idea to multiple investors. Requests to support the idea are received by the innovation system from the investors. The requests to support the idea include an investment amount. After the aggregate investment amount from every investor is greater than a threshold, the innovation system approves the idea. The innovation system then rewards the investors that supported an approved idea.

Abstract: An integrated wind and hydro power generation system includes at least one wind turbine generator device configured to generate output power from a common cavity being occupied by water and air. The hydro generator device is powered by water flow, while the wind generator is primarily powered by the vacuum occurring with the water's exit from the cavity.

Abstract: The invention relates to urea derivatives of formula (I) as inhibitors of glycogen synthase kinase 3?, GSK-3, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which GSK-3 is involved, such as Alzheimer's disease or non-insulin dependent diabetes mellitus.

Abstract: A mechanism for varying the stroke length of an internal combustion engine during each cycle of operation includes a gear set with a first gear non-rotatably mounted to the engine block and a second gear having teeth formed on an inner surface thereof meshing with the first gear to achieve a uniform mechanical crank arm and a variable cam arm for producing a varying length of piston reciprocation throughout the overall stroke cycle of the engine. The orientation of the crank arm and the cam arm relative to the axis of piston reciprocation is selected for causing the crank arm and the cam arm to cooperatively produce a positive torque on the crankshaft at the top dead center position of the piston. The gear set is also selectively configured and dimensioned to achieve a predetermined ratio of the length of the cam arm to the length of the crank arm.

Abstract: A transmission system for transmitting a rotary motion input to a rotary motion output utilizing hypocycloid motion multiplication is disclosed. The system comprises an input mechanism, at least one hydraulic transmission means, an output mechanism and an output bladder linkage. The input mechanism includes a plurality of rollers that each capture at least one arcuate linkage against an inside surface of a cylindrical hub, causing the linkage to rotate as the roller traverses thereacross and compress one of a plurality of input bladders. The compressed input bladders cause an output bladder to expand to drive the output mechanism in reciprocal linear motion, which the output mechanism converts to rotational motion at the rotary motion output. The output mechanism can be located proximate to, or distal from, the input mechanism.

Abstract: Provided are thiadiazolidine compounds of formula I wherein R1 is an organic group having at least 8 atoms selected from C or O, which is not linked directly to the N through a —C(O)— and comprising at least an aromatic ring, and their pharmaceutical compositions. These compounds are selective GSK-3 inhibitors and have improved bioavailability. They are useful for the treatment of GSK-3 mediated diseases, among others Alzheimer's disease, type II diabetes, depression and brain injury.

Abstract: A towing device for towing a motorcycle comprising a base having a first end that slides horizontally into a receiver hitch of the vehicle; a platform extending outwardly from a second end of the base; an arc-shaped cradle for cradling a front wheel of the motorcycle; the cradle is divided into a front portion attached atop the platform and a ramp pivotally attached to the front portion of the cradle via a hinge, the ramp'can pivot to an up position and a down position, wherein the down position allows the front wheel of the motorcycle to be rolled into the front portion of the cradle, the ramp can be secured in the up position via a securing means; and a side support component extending upwardly from the platform, the side support component functions to support the front wheel of the motorcycle when in the cradle.

Abstract: A method and apparatus for scanning for or removing malware from a computer device. Under normal circumstances, the computer device is controlled by a first operating system installed in a memory of the device. In order to scan for or remove the malware from the computer device, control of the computer device is passed from the first operating system to a second operating system and, under the control of the second operating system, the device is either scanned for malware or the malware is removed. This allows malware to be detected or removed, even if it has affected the first operating system in some way in order to evade detection or removal.

Abstract: The GapC plasmin binding protein genes of Streptococcus dysgalactiae (S. dysgalactiae), Streptococcus agalactiae (S. agalactiae), Streptococcus uberis (S. uberis), Streptococcus parauberis (S. parauberis), and Streptococcus iniae (S. iniae) are described, as well as the recombinant production of the GapC proteins therefrom. Also described is the use of the GapC proteins from those species in vaccine compositions to prevent or treat bacterial infections in general, and mastitis in particular.

Abstract: The CAMP factor gene of Streptococcus uberis (S. uberis) is described, as well as the recombinant production of CAMP factor therefrom. Also disclosed are chimeric CAMP factor constructs, including CAMP factor epitopes from more than one bacterial species. The CAMP factors and chimeras including the same can be used in immunogenic compositions for the prevention and treatment of bacterial infections.

Abstract: Provided are thiadiazolidine compounds of formula I wherein R1 is an organic group having at least 8 atoms selected from C or O, which is not linked directly to the N through a —C(O)— and comprising at least an aromatic ring, and their pharmaceutical compositions. These compounds are selective GSK-3 inhibitors and have improved bioavailability. They are useful for the treatment of GSK-3 mediated diseases, among others Alzheimer's disease, type II diabetes, depression and brain injury.

Abstract: The present invention relates to the use of N-(2-thiazolyl)-amide derivatives of formula (I), for the treatment and/or prophylaxis of a disease in which glycogen synthase kinase 3 (GSK-3) is involved, especially neurodegenerative diseases, such as Alzheimer's disease, or non-insulin dependent diabetes mellitus.

Abstract: The present invention relates to the use of N-(2-thiazolyl)-amide derivatives of formula (I) for the treatment and/or prophylaxis of a disease in which glycogen synthase kinase 3 (GSK-3) is involved, especially neurodegenerative diseases, such as Alzheimer's disease, or non-insulin dependent diabetes mellitus.

Abstract: The present invention is a chemical composition including: Use of the compound with the chemical formula can be applied in pharmaceutical compositions for the treatment of psoriasis.

Abstract: The invention relates to urea derivatives of formula (I) as inhibitors of glycogen synthase kinase 3?, GSK-3, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use for the treatment and or prophylaxis of a disease in which GSK-3 is involved, such as Alzheimer's disease or non-insulin dependent diabetes mellitus.

Abstract: Provided are thiadiazolidine compounds of formula I wherein R1 is an organic group having at least 8 atoms selected from C or O, which is not linked directly to the N through a —C(O)— and comprising at least an aromatic ring, and their pharmaceutical compositions. These compounds are selective GSK-3 inhibitors and have improved bioavailability. They are useful for the treatment of GSK-3 mediated diseases, among others Alzheimer's disease, type II diabetes, depression and brain injury.